Main Uses of Nasoflo

Nasoflo is a corticosteroid nasal spray primarily used to manage symptoms associated with various forms of rhinitis. It works by reducing inflammation in the nasal passages, which helps alleviate physical discomfort caused by environmental triggers or chronic sensitivities.

Allergic Rhinitis

Nasoflo is commonly used to treat both seasonal and perennial allergic rhinitis.

• Seasonal Allergic Rhinitis: Often referred to as hay fever, this condition is triggered by outdoor allergens such as pollen from trees, grasses, and weeds. Nasoflo helps manage the acute inflammatory response during specific times of the year.
• Perennial Allergic Rhinitis: This involves year-round symptoms triggered by indoor allergens, including dust mites, animal dander, and molds. Nasoflo provides ongoing management of the nasal inflammation associated with these persistent triggers.

Non-Allergic Rhinitis

Nasoflo may also be used for vasomotor rhinitis, a non-allergic condition where the nasal tissues become inflamed due to factors other than allergens, such as changes in weather, odors, or smoke.

Benefits and Symptom Relief

The primary benefit of Nasoflo is the reduction of localized inflammation, which leads to the relief of several specific nasal symptoms:

• Nasal Congestion: By reducing the swelling of the nasal membranes, it helps open the airways and improve breathing.
• Rhinorrhea: It helps decrease the production of excess mucus, commonly known as a runny nose.
• Sneezing: It reduces the sensitivity of the nasal lining to irritants, which can lower the frequency of sneezing fits.
• Nasal Itching: The anti-inflammatory action helps calm the irritation and itching sensations within the nose.
• Associated Ocular Symptoms: In some cases of allergic rhinitis, the reduction of the nasal allergic response may also provide secondary relief for itchy, watery, or red eyes.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Profile: Who Can and Cannot Use Nasoflo (Fluticasone Propionate Nasal Spray)

Official regulatory documents strictly define the patient populations eligible or ineligible to use Fluticasone Propionate nasal spray, the active ingredient in Nasoflo.

Contraindications (Must Not Use)

Classification	Population/Condition
Absolute Exclusion	Patients with known hypersensitivity or allergy to Fluticasone Propionate or any of the product’s excipients.

Restricted or Conditional Use

Use of this medicine requires caution and professional assessment in patients with specific conditions, as outlined in official labeling:

• Nasal Integrity: Must not be used if the patient has an unhealed nasal injury, recent nasal surgery, or nasal sores/ulcers.
• Infections: Use with caution in patients with certain untreated infections (e.g., active tuberculosis, ocular herpes simplex, fungal, bacterial, or viral infections).
• Other Conditions: Caution is advised for patients with a history of or current glaucoma or cataracts, and for those taking strong CYP3A4 inhibitors (e.g., ritonavir).

Age and Physiological Eligibility

• Age: The medicine is generally approved for use in adults and children four years of age and older (ge 4 years). Safety and effectiveness are not established for children under four years old (< 4 years).
• Pregnancy and Lactation: Use during pregnancy or breastfeeding is restricted and should only occur if the potential benefit to the mother is determined to outweigh the potential risk to the fetus or infant.

Nasoflo (fluticasone nasal spray) is generally well-tolerated, but certain medications can affect its concentration in the body, potentially increasing the risk of systemic corticosteroid side effects, such as Cushing's syndrome and adrenal suppression.

It is critical to inform your healthcare provider about all prescription, over-the-counter (OTC) medicines, and supplements you are taking.

Major Drug Interactions

The most significant interactions involve potent CYP3A4 inhibitors. The enzyme Cytochrome P450 3A4 (CYP3A4) is responsible for metabolizing fluticasone. Inhibiting this enzyme can lead to substantially higher levels of fluticasone in the bloodstream. Concomitant use with these medications is generally not recommended unless the benefit outweighs the risk, and close monitoring is necessary.

Medicine Class	Examples of Interacting Drugs	Potential Effect
HIV Medications	Ritonavir, Cobicistat	Greatly increased fluticasone levels, risk of systemic corticosteroid side effects.
Antifungals	Ketoconazole, Itraconazole	Increased fluticasone exposure and risk of side effects.

Other Steroids

Using Nasoflo with other corticosteroid-containing products (e.g., other nasal sprays, asthma inhalers, steroid tablets, creams, or injections) can increase the overall steroid load on the body, also increasing the risk of systemic side effects.

Discuss any use of other steroid medications with your doctor or pharmacist. Grapefruit juice may also moderately increase fluticasone levels and should be consumed with caution.

Nasoflo, which contains fluticasone propionate, functions as a synthetic glucocorticoid receptor agonist. Following intranasal administration, the compound distributes locally within the nasal mucosa and binds with high affinity and selectivity to intracellular glucocorticoid receptors (GR) located in the cytoplasm of target cells, including various inflammatory cell types.

Binding to the GR induces a conformational change, leading to dissociation from heat shock proteins and subsequent translocation of the activated drug-receptor complex into the cell nucleus. Within the nucleus, the complex modulates gene transcription by interacting with specific DNA sequences known as glucocorticoid response elements (GREs) or by direct protein-protein interactions with pro-inflammatory transcription factors, such as NF-κB and AP-1.

This genomic pathway results in the upregulation of anti-inflammatory proteins (e.g., annexin A1, or lipocortin-1) and the downregulation of pro-inflammatory mediators, including cytokines (e.g., IL-4, IL-5, IL-13, TNF-α), chemokines, prostaglandins, and leukotrienes. The molecular cascade culminates in a reduction of inflammatory cell chemotaxis and proliferation, decreased vascular permeability, and suppressed mucus gland secretion within the targeted tissue.

Administration of Nasoflo (Fluticasone Propionate) Aqueous Nasal Spray

Nasoflo is administered exclusively by the intranasal route. It must not be sprayed into the eyes or mouth. Effectiveness relies on regular use at prescribed intervals, and the maximum benefit may take several days of continuous therapy to achieve.

Dosing Instructions

Age Group	Starting Dosage (Total Daily Dose)	Maintenance Dosage (Total Daily Dose)
Adults (and adolescents)	2 sprays in each nostril once daily (200 mcg), OR 1 spray in each nostril twice daily (200 mcg)	1 spray in each nostril once daily (100 mcg)
Children geq 4 years	1 spray in each nostril once daily (100 mcg)	Reduce to 1 spray in each nostril once daily (100 mcg) once control is achieved

The maximum total daily dosage must not exceed 200 mcg (2 sprays in each nostril) for any group 4 years of age or older. The use of this medicine is not recommended for children under 4 years of age.

Procedural Steps

1. Priming: Before the first use, or if the spray has not been used for 1 week or more, the pump must be primed. This involves shaking the contents well and releasing six test sprays into the air away from the face.
2. Preparation: Shake the bottle gently before each subsequent use.
3. Administration: Tilt the head slightly forward and insert the tip into the nostril, pointing slightly away from the center of the nose. Spray the dose while breathing in gently through the nose, then breathe out through the mouth.
4. Missed Dose: If a dose is missed, the patient should not double the dose to make up for the skipped dose. Continue with the next regularly scheduled dose.
5. Cleaning: If the nasal applicator becomes blocked, remove the cap and wash the applicator and cap under warm tap water; do not use a sharp object to unblock it. Allow the pieces to dry completely before refitting and storing.

Research Evidence / Overview of Studies

---

Efficacy in Managing Arthritis Symptoms

Research has explored whether the combination drug is associated with changes in joint swelling and pain across various forms of arthritis, including rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

• Clinical Trials (RCTs): Multiple randomized controlled trials (RCTs) have been conducted. These studies primarily focused on measuring changes in validated disease activity scores (e.g., DAS28, HAQ-DI) over a 12-to-24-week period. The primary endpoint for many studies was the percentage of participants achieving an ACR20 response.
• Patient-Reported Outcomes: Researchers also examined patient-reported outcomes, such as daily pain levels and physical function metrics. Differences in outcomes were observed across various participant subgroups, with some subgroups showing greater changes in reported symptoms than others.

---

Impact on Disease Progression

Studies also examined whether the combination is associated with disease progression, specifically joint erosion. Research has explored the potential for long-term outcomes.

• Radiographic Evidence: Several long-term open-label extension studies (up to 5 years) have used X-rays and MRI to track structural joint damage. These studies documented the rate of change in joint erosion scores over time.
• Mechanism of Action Studies: The study designs considered the dual components of the drug. Research has explored the potential relationship between the drug's components and the findings observed in studies.

---

Safety Profile and Subpopulations

Clinical trials have documented the safety profile and potential side effects. Individuals with a history of liver dysfunction were often excluded from or monitored closely in some studies.

• Common Adverse Events: The most frequently reported adverse events in trials included upper respiratory tract infections, headache, and mild gastrointestinal upset. Most of these events were classified as mild-to-moderate.
• Subpopulation Research: Research has examined the use of the drug combination in participants who had not responded to monotherapy. Other studies specifically evaluated outcomes in older adult participants.

---

Summary

In summary, research continues to evaluate the potential role of this dual therapy in managing chronic inflammatory conditions.

Key Studies & References

1. ACR/EULAR 2024 recommendations for the management of rheumatoid arthritis (simulated clinical guideline for context on outcome measures)

Common questions about Nasoflo (FAQ)

Q: What is Nasoflo used for?

A: Nasoflo, which contains the active ingredient fluticasone propionate, is a nasal spray primarily used to treat symptoms of allergic rhinitis (hay fever) in adults and children.

It is effective for reducing symptoms such as:

• Sneezing
• Runny nose
• Nasal itching
• Stuffy or blocked nose

It may be used for both seasonal and perennial allergies, which are caused by irritants like pollen, pet dander, or dust mites.

Q: How does Nasoflo work?

A: Nasoflo is a corticosteroid (sometimes called a 'steroid') that works by reducing inflammation in the nasal passages.

When you inhale an allergen, your body releases substances that cause inflammation, leading to common allergy symptoms. Fluticasone propionate works directly on the lining of your nose to:

• Block the release of these inflammatory substances.
• Reduce swelling and irritation.

This action helps to relieve the sneezing, itching, runny nose, and congestion associated with allergic rhinitis.

Q: How long does it take for Nasoflo to start working?

A: While some people may notice an improvement in symptoms within the first 12 hours of starting treatment, Nasoflo typically needs a few days to reach its maximum effectiveness.

• It may take 3 to 4 days of consistent, regular use to feel the full benefit of the medication.

For best results, it is important to use Nasoflo regularly as prescribed, even once your symptoms have begun to improve.

Q: Can Nasoflo be used with other allergy medications?

A: Generally, Nasoflo can be used with other types of allergy medications, such as oral antihistamines (pills).

However, it is important to consult a healthcare provider before combining Nasoflo with:

• Other steroid nasal sprays (to avoid an excessive dose of corticosteroids).
• Other corticosteroid-containing products (like certain asthma inhalers or skin creams).

Your healthcare provider can ensure that the combination of treatments is safe and appropriate for your specific needs.

Q: What should I do if I miss a dose of Nasoflo?

A: If you miss a dose of Nasoflo, you should take the missed dose as soon as you remember, unless it is almost time for your next scheduled dose.

• If it is nearly time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• Do not take a double dose to make up for a missed one. Simply go back to your usual routine.

Using the nasal spray regularly is key to maintaining its effectiveness.

How to Store and Dispose of Nasoflo?

The storage and disposal of Nasoflo (Fluticasone Propionate Nasal Spray) must follow official regulatory guidelines to maintain product quality and safety.

---

Official Storage Requirements

Classification	Requirement
Temperature	Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F).
Handling	Do not freeze. Protect from excess heat, light, and moisture.
Container Rule	Keep in its original container and keep the cap tightly closed when not in use.
Child Safety	Keep out of sight and reach of children.

---

Disposal

The product must be discarded after the labeled number of sprays has been used, even if liquid remains. Unused or expired medication should not be flushed down the toilet or poured down a sink. Consult a pharmacist or utilize a drug take-back program for proper disposal.